Heron Therapeutics (Heron Therapeutics) Days Sales Outstanding : 165.17 (As of Dec. 2023)

View and export this data going back to 1987. Start your Free Trial

What is Heron Therapeutics Days Sales Outstanding?

Heron Therapeutics's average Accounts Receivable for the three months ended in Dec. 2023 was $62.0 Mil. Heron Therapeutics's Revenue for the three months ended in Dec. 2023 was $34.2 Mil. Hence, Heron Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 165.17.

The historical rank and industry rank for Heron Therapeutics's Days Sales Outstanding or its related term are showing as below:

HRTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 130.69 Med: 165.88 Max: 559.34
Current: 174.75

During the past 13 years, Heron Therapeutics's highest Days Sales Outstanding was 559.34. The lowest was 130.69. And the median was 165.88.

HRTX's Days Sales Outstanding is ranked worse than
80.47% of 891 companies
in the Biotechnology industry
Industry Median: 71.97 vs HRTX: 174.75

Heron Therapeutics's Days Sales Outstanding increased from Dec. 2022 (143.19) to Dec. 2023 (165.17).

Heron Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Heron Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heron Therapeutics Days Sales Outstanding Chart

Heron Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

130.69

168.27

163.48

148.39

161.16

Heron Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															143.19	159.45	184.07	203.91	165.17

Competitive Comparison of Heron Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, Heron Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Heron Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heron Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Heron Therapeutics's Days Sales Outstanding falls into.

Heron Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Heron Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (52.049	+	60.137)	/	2 )	/	127.044	*	365
=	56.093					/	127.044	*	365
=	161.16

Heron Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (63.795	+	60.137)	/	2 )	/	34.233	*	365 / 4
=	61.966					/	34.233	*	365 / 4
=	165.17

Heron Therapeutics (NAS:HRTX) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Heron Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Heron Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Heron Therapeutics (Heron Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heron Therapeutics Inc (NAS:HRTX) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

AXD2:Germany AXD2:Germany

Address

4242 Campus Point Court, Suite 200, San Diego, CA, USA, 92121

Website

https://www.herontx.com

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.

Executives

William P Forbes	officer: EVP, Chief Development Officer	C/O SALIX PHARMACEUTICALS, LTD., 8510 COLONNADE CENTER DRIVE, RALEIGH NC 27615
Adam Morgan	other: See Footnote 2	1055B POWERS PLACE, ALPHARETTA GA 30009
Ira Duarte	officer: EVP, Chief Financial Officer	1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Craig A Collard	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Kevin Kotler	director	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Velan Capital Master Fund Lp	other: See Footnote 2	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc	other: See Footnote 2	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc	other: See Footnote 2	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp	other: See Footnote 2	1055B POWERS PLACE, ALPHARETTA GA 30009
David Efraim Rosen	other: See Footnote 1	155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Rubric Capital Management Lp	other: See Footnote 1	155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Balaji Venkataraman	other: See Footnote 2	FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Kimberly Manhard	director	C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Craig A Johnson	director	C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Waage Christian	director	RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121